1. bookVolume 63 (2013): Edizione 3 (September 2013)
Dettagli della rivista
Prima pubblicazione
28 Feb 2007
Frequenza di pubblicazione
4 volte all'anno
Accesso libero

Drug interactions with statins

Pubblicato online: 22 Oct 2013
Volume & Edizione: Volume 63 (2013) - Edizione 3 (September 2013)
Pagine: 277 - 293
Dettagli della rivista
Prima pubblicazione
28 Feb 2007
Frequenza di pubblicazione
4 volte all'anno

1. R. J. Herman, Drug interactions and the statins, CMAJ 161 (1999) 1281-1286.Search in Google Scholar

2. Cardiovascular Drugs, in Martindale: The Complete Drug Reference, 36th ed. (Ed. S. C. Sweetman), Pharmaceutical Press, London 2009, pp. 1155-1434.Search in Google Scholar

3. T. Uno, K. Sugimoto, K. Sugawara and T. Tateishi, The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazol, Ther. Drug Monit. 30 (2008) 276-281; DOI: 10.1097/FTD.0b013e31816e2d8e.10.1097/FTD.0b013e31816e2d8eSearch in Google Scholar

4. C. Bolego, R. Baetta, S. Bellosta, A. Corsini and R. Paoletti, Safety considerations for statins, Curr. Opin. Lipidol. 13 (2002) 637-644.10.1097/00041433-200212000-00007Search in Google Scholar

5. H. M. Devold, E. Molden, S. Skurtveit and K. Furu, Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy, Br. J. Clin. Pharmacol. 67 (2009) 234-241; DOI: 10.1111/j.1365-2125.2008.03345.x.10.1111/j.1365-2125.2008.03345.xSearch in Google Scholar

6. E. Molden, K. S. Andersson and D. Jacobsen, Interactions between statins and macrolide antibiotics, Tidsskr. Nor. Laegeforen 127 (2007) 1660-1661.Search in Google Scholar

7. A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paolett and F. Bernini, New insights into the pharmacodynamic and pharmacokinetic properties of statins, Pharmacol. Ther. 84 (1999) 413-428.10.1016/S0163-7258(99)00045-5Search in Google Scholar

8. C. M. White, A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin, J. Clin. Pharmacol. 42 (2002) 963-970.10.1177/009127002401102876Search in Google Scholar

9. R. Bhindi, O. Ormerod, J. Newton, A. P. Banning and L. Tesla, Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 101 (2008) 915-925; DOI: 10.1093/qjmed/ hcn089.Search in Google Scholar

10. P. J. Neuvonen, M. Niemi and J. T. Backman, Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance, Clin. Pharmacol. Ther. 80 (2006) 565-581.10.1016/j.clpt.2006.09.00317178259Search in Google Scholar

11. K. M. Giacomini, S. M. Huang, D. J. Tweedie, L. Z. Benet, K. L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K. M. Hillgren, K. A. Hoffmaster, T. Ishikawa, D. Keppler, R. B. Kim, C. A. Lee, M. Niemi, J. W. Polli, Y. Sugiyama, P. W. Swaan, J. A. Ware, S. H. Wright, S. W. Yee, M. J. Zamek-Gliszczynski and L. Zhang, Membrane transporters in drug development, Nat. Rev. Drug Discov. 9 (2010) 215-236; DOI: 10.1038/nrd3028.10.1038/nrd3028332607620190787Search in Google Scholar

12. M. Karlgren, G. Ahlin, C. A. Bergström, R. Svensson, J. Palm and P. Artursson, In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions, Pharm. Res. 29 (2012) 411-426; DOI: 10.1007/s11095-011-0564-9.10.1007/s11095-011-0564-9326487321861202Search in Google Scholar

13. E. Link, S. Parish, J. Armitage, L. Bowman, S. Heath, F. Matsuda, I. Gut, M. Lathrop and R. Collins, SLCO1B1 variants and statin-induced myopathy - a genomewide study, N. Engl. J. Med.359 (2008) 789-799; DOI: 10.1056/NEJMoa0801936.10.1056/NEJMoa080193618650507Search in Google Scholar

14. D. Voora, S. H. Shah, I. Spasojevic, S. Ali, C. R. Reed, B. A. Salisbury and G. S. Ginsburg, The SLCO1B1*5 genetic variant is associated with statin-induced side effects, J. Am. Coll. Cardiol. 54 (2009) 1609-1616; DOI: 10.1016/j.jacc.2009. in Google Scholar

15. J. P. F. Bai, Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics, Drug Metab. Pharmacokin. 25 (2010) 62-71.10.2133/dmpk.25.6220208389Search in Google Scholar

16. J. Mwinyi, A. Johne, S. Bauer, I. Roots and T. Gerloff, Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetic, Clin. Pharmacol. Ther. 75 (2004) 415-421.10.1016/j.clpt.2003.12.01615116054Search in Google Scholar

17. M. Niemi, E. Schaeffeler, T. Lang, M. F. Fromm, M. Neuvonen, C. Kyrklund, J. T. Backman, R. Kerb, M. Schwab, P. J. Neuvonen, M. Eichelbaum and K. T. Kivistö, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1), Pharmacogenetics 14 (2004) 429-440.10.1097/01.fpc.0000114750.08559.3215226675Search in Google Scholar

18. Y. Shitara, Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions, Drug Metab. Pharmacokin. 26 (2011) 220-227; DOI: 10.2133/dmpk.DMPK-10-RV-094.10.2133/dmpk.DMPK-10-RV-09421297316Search in Google Scholar

19. K. Morimoto, T. Oishi, S. Ueda, M. Ueda, M. Hosokawa and K. Chib, A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy, Drug Metab. Pharmacokin. 19 (2004) 453-455.10.2133/dmpk.19.45315681900Search in Google Scholar

20. Y. Y. Lau, H. Okochi, Y. Huang and L. Z. Benet, Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems, J. Pharmacol. Exp. Ther. 316 (2006) 762-771.10.1124/jpet.105.09308816258024Search in Google Scholar

21. G. A. Schmidt, J. D. Hoehns, J. L. Purcell, R. L. Friedman and Y. Elhawi, Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir, J. Am. Board. Fam. Med. 20 (2007) 411-416.10.3122/jabfm.2007.04.06018717615423Search in Google Scholar

22. V. Borders-Hemphill, Concurrent use of statins and amiodarone, Consult. Pharm. 24 (2009) 372-379.10.4140/TCP.n.2009.37219555146Search in Google Scholar

23. S. Lam, N. Partovi, L. S. Ting, and M. H. Ensom, Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?, Ann. Pharmacother. 42 (2008) 1037-1047; DOI: 10.1345/aph.1K628.10.1345/aph.1K628Search in Google Scholar

24. D. Williams and J. Freely, Pharmacokinetic-pharmacodynamic drug interactions with HMGCoA reductase inhibitors, Clin. Pharmacokinet. 41 (2002) 343-370.10.2165/00003088-200241050-0000312036392Search in Google Scholar

25. S. Bellosta, R. Paoletti and A. Corsini, Safety of statins: focus on clinical pharmacokinetics and drug interactions, Circulation 109 (2004) III50-III57; DOI: 10.1161/01.CIR.0000131519.15067.1f.10.1161/01.CIR.0000131519.15067.1f15198967Search in Google Scholar

26. K. Ohyama, M. Nakajima, M. Suzuki, N. Shimada, H. Yamazaki and T. Yokoi, Inhibitory effects of amiodarone and its N-desethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions, Br. J. Clin. Pharmacol. 49 (2000) 244-253.Search in Google Scholar

27. U. M. Chouhan, S. Chakrabarti and L. J. Millward, Simvastatin interaction with clarithromycin and amiodarone causing myositis, Ann. Pharmacother. 39 (2005) 1760-1761.10.1345/aph.1G19516159992Search in Google Scholar

28. A. Marot, J. Morelle, V. A. Chouinard, M. Jadoul, M. Lambert and N. Demoulin, Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature, Acta Clin. Belg. 66 (2011) 134-136.Search in Google Scholar

29. B. Ricaurte, A. Guirguis, H. C. Taylor and D. Zabriskie, Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity, Ann. Pharmacother. 40 (2006) 753-757.10.1345/aph.1G46216537817Search in Google Scholar

30. A. Alsheikh-Ali and R. Karas, Adverse events with concomitant amiodarone and statin therapy, Prev. Cardiol. 8 (2005) 95-97.10.1111/j.1520-037X.2005.4060.x15860984Search in Google Scholar

31. S. Karimi, A. Hough, C. Beckey and D. Parra, Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center, J. Manag. Care Pharm. 16 (2010) 472-481.10.18553/jmcp.2010.16.7.47220726676Search in Google Scholar

32. DRUGDEX®/MICROMEDEX®. Statins. Healthcare Series for Windows. Micromedex Thomson Healthcare. 2012. Retrieved from:http://www.thomsonhc.com/home/dispatch (accessed July 6, 2012).Search in Google Scholar

33. G. W. Amsden, O. Kuye and G. C. Wei, A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers, J. Clin. Pharmacol. 42 (2002) 444-449.10.1177/00912700222011373Search in Google Scholar

34. G. W. Amsden, Macrolides versus azalides: a drug interaction update, Ann. Pharmacother. 29 (1995) 906-917.10.1177/1060028095029009138547740Search in Google Scholar

35. M. P. Pai, D. M. Graci and G. W. Amsden, Macrolide drug interactions: an update, Ann. Pharmacother.34 (2000) 495-513.10.1345/aph.1913810772438Search in Google Scholar

36. J. W. Grunden and K. A. Fisher, Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin, Ann. Pharmacother. 31 (1997) 859-863.10.1177/1060028097031007109220046Search in Google Scholar

37. M. Z. Skrabal, J. A. Stading, C. A. Cannella and M. S. Monaghan, Two cases of rhabdomyolysis associated with high-dose simvastatin, Am. J. Health. Syst. Pharm. 60 (2003) 578-581.10.1093/ajhp/60.6.57812659062Search in Google Scholar

38. J. Strandell, A. Bate, S. Hägg and I. R. Edwards, Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction, Br. J. Clin. Pharmacol. 68 (2009) 427-434; DOI: 10.1111/j. 1365-2125.2009.03473.x.Search in Google Scholar

39. R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. Wood and G. R. Wilkinson, Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein, Pharm. Res. 16 (1999) 408-414.10.1023/A:1018877803319Search in Google Scholar

40. C. Marzolini, E. Paus, T. Buclin and R. B. Kim, Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance, Clin. Pharmacol. Ther. 75 (2004) 13-33.10.1016/j.clpt.2003.09.01214749689Search in Google Scholar

41. S. Eberl, I. Bachmakov, F. Dörje and M. F. Fromm, The effect of macrolide antibiotics on the function of the drug transporter P-glycoprotein, Naunyn-Schmiedeberg’s Arch. Pharmacol. 371 (2005) R145.10.1007/s00210-005-1025-y15900513Search in Google Scholar

42. J. Rengelshausen, C. Goggelmann, J. Burhenne, K. D. Riedel, J. Ludwig, J. Weiss, G. Mikus, I. Walter-Sack and W. Haefeli, Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction, Br. J. Clin. Pharmacol. 56 (2003) 32-38.10.1046/j.1365-2125.2003.01824.x188433712848773Search in Google Scholar

43. T. Jacobson, Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors, Am. J. Cardiol. 94 (2004) 1140-1146.10.1016/j.amjcard.2004.07.08015518608Search in Google Scholar

44. A. Seithel, S. Eberl, K. Singer, D. Auge, G. Heinkele, N. B. Wolf, F. Dörje, M. F. Fromm and J. König, The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3, Drug Metab. Dispos. 35 (2007) 779-786.10.1124/dmd.106.01440717296622Search in Google Scholar

45. M. Hirano, K. Maeda, Y. Shitara and Y. Sugiyama, Drug-drug interaction between pitavastatin and various drugs via OATP1B1, Drug Metab. Dispos. 34 (2006) 1229-1236.10.1124/dmd.106.00929016595711Search in Google Scholar

46. R. D. Sawant, Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin, Can. J. Clin. Pharmacol. 16 (2009) 78-79.Search in Google Scholar

47. M. Ishigami, M. Uchiyama, T. Kondo, H. Iwabuchi, S. Inoue, W. Takasaki, T. Ikeda, T. Komai, K. Ito and Y. Sugiyama, Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions, Pharm. Res. 18 (2001) 622-631.10.1023/A:1011077109233Search in Google Scholar

48. K. T. Kivistö, T. Kantola and P. J. Neuvonen, Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin, Br. J. Clin. Pharmacol. 46 (1998) 49-53.10.1046/j.1365-2125.1998.00034.x18739809690949Search in Google Scholar

49. K. Akram, S. Rao and M. Parker, A lesson for everyone in drug-drug interactions (letter), Int. J. Cardiol. 118 (2007) 19-20.10.1016/j.ijcard.2006.11.23517368833Search in Google Scholar

50. R. Gilad and Y. Lampl, Rhabdomyolysis induced by simvastatin and ketoconazole treatment, Clin. Neuropharmacol. 22 (1999) 295-297.Search in Google Scholar

51. H. Itakura, D. Vaughn, D. Haller and P. O’Dwyer, Rhabdomyolysis from cytochrome P-450 interaction of ketoconazole and simvastatin in prostate cancer, J. Urol. 169 (2003) 613; DOI: 10. 1016/S0022-5347(05)63967-5.Search in Google Scholar

52. C. Stein, S. Goel and R. Ghavamian, Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy, Invest. New Drugs25 (2007) 277-278.10.1007/s10637-006-9032-5Search in Google Scholar

53. O. Findling, N. Meier, J. Sellner, K. Nedeltchev and M. Arnold, Clinical reasoning: rhabdomyolysis after combined treatment with simvastatin and fluconazole, Neurology 71 (2008) 34-37; DOI: 10.1212/01.wnl.0000327566.57661.09.10.1212/01.wnl.0000327566.57661.09Search in Google Scholar

54. C. C. Franz, M. Bruggisser, S. Krähenbühl and A. E. Rätz Bravo, Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole, Praxis (Bern 1994) 100 (2011) 273-284; DOI: 10.1024/1661-8157/a000491.10.1024/1661-8157/a000491Search in Google Scholar

55. R. Hazin, J. Y. Abuzetun, M. Suker and J. Porter, Rhabdomyolysis induced by simvastatin-fluconazole combination, J. Natl. Med. Assoc. 100 (2008) 444-446.10.1016/S0027-9684(15)31280-3Search in Google Scholar

56. A. Shaukat, M. Benekli, G. D. Vladutiu, J. L. Slack, M. Wetzler and M. R. Baer, Simvastatin-fluconazole causing rhabdomyolysis, Ann. Pharmacother. 37 (2003) 1032-1035.10.1345/aph.1C467Search in Google Scholar

57. N. E. Azie, D. C. Brater, P. A. Becker, D. R. Jones and S. D. Hall, The interaction of diltiazem with lovastatin and pravastatin, Clin. Pharmacol. Ther. 64 (1998) 369-377.10.1016/S0009-9236(98)90067-4Search in Google Scholar

58. O. Mousa, D. C. Brater, K. J. Sunblad and S. D. Hall, The interaction of diltiazem with simvastatin, Clin. Pharmacol. Ther. 67 (2000) 267-274.10.1067/mcp.2000.10460910741630Search in Google Scholar

59. Y. Sugiyama, N. Mimura, T. Kuwabara, H. Kobayashi, J. Ushiki and E. Fuse, Effect of benidipine on simvastatin metabolism in human liver microsomes, Drug Metab. Pharmacokinet. 22 (2007) 199-205.10.2133/dmpk.22.19917603221Search in Google Scholar

60. J. J. Lewin, J. M. Nappi and M. H. Taylor, Rhabdomyolysis with concurrent atorvastatin and diltiazem, Ann. Pharmacother. 36 (2002) 1546-1549.10.1345/aph.1A48112243603Search in Google Scholar

61. R. Peces and A. Pobes, Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem, Nephron. 89 (2001) 117-118.10.1159/00004605611528245Search in Google Scholar

62. T. Prueksaritanont, B. Ma, C. Tang, Y. Meng, C. Assang, P. Lu, P. J. Reider, J. H. Lin and T. A. Baillie, Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations, Br. J. Clin. Pharmacol. 47 (1999) 291-298.Search in Google Scholar

63. M. Jasiñska, J. Owczarek and D. Orszulak-Michalak, The influence of simvastatin at high dose and diltiazem on myocardium in rabbits, the biochemical study, Acta Pol. Pharm. 63 (2006) 386-390.Search in Google Scholar

64. T. Kantola, K. T. Kivisto and P. J. Neuvonen, Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations, Clin. Pharmacol. Ther. 64 (1998) 177-182.10.1016/S0009-9236(98)90151-5Search in Google Scholar

65. H. Satoh, F. Yamashita, M. Tsujimoto, H. Murakami, N. Koyabu, H. Ohtani and Y. Sawada, Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B, DrugMetab. Dispos. 33 (2005) 518-523.10.1124/dmd.104.00233715640378Search in Google Scholar

66. P. Li, P. S. Callery, L. S. Gan and S. K. Balani, Estearase inhibition by grapefruit juice flavonoids leading to a new drug interaction, Drug Metab. Dispos. 35 (2007) 1203-1208.10.1124/dmd.106.01390417452418Search in Google Scholar

67. J. J. Lilja, K. T. Kivistö and P. J. Neuvonen, Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin, Clin. Pharmacol. Ther. 66 (1999) 118-127.10.1053/cp.1999.v66.10045300110460065Search in Google Scholar

68. J. J. Lilja, K. T. Kivistö and P. J. Neuvonen, Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors, Clin. Pharmacol. Ther. 64 (1998) 477-483.Search in Google Scholar

69. J. J. Lilja, M. Neuvonen and P. J. Neuvonen, Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin, Br. J. Clin. Pharmacol. 58 (2004) 56-60.10.1111/j.1365-2125.2004.02095.x188453915206993Search in Google Scholar

70. I. Fukazawa, N. Uchida, E. Uchida and H. Yasuhara, Effects of grapefruit on pharmacokinetics of atorvastatin and pravastatin in Japanese, Br. J. Clin. Pharmacol. 57 (2003) 448-455.10.1046/j.1365-2125.2003.02030.x188446915025743Search in Google Scholar

71. H. Ando, S. Tsuruoka, H. Yanagihara, K. Sugimoto, M. Miyata, Y. Yamazoe, T. Takamura, S. Kaneko and A. Fujimura, Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin, Br. J. Pharmacol. 60 (2005) 494-497.10.1111/j.1365-2125.2005.02462.x188494016236039Search in Google Scholar

72. Y. Koitabashi, T. Kumai, N. Matsumoto and M. Watanabe, Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects, Life Sci. 78 (2006) 2852-2859.10.1016/j.lfs.2005.11.00616412477Search in Google Scholar

73. A. V. Sorokin, B. Duncan, R. Panetta and P. D. Thompson, Rhabdomyolysis associated with pomegranate juice consumption, Am. J. Cardiol. 98 (2006) 705-706.10.1016/j.amjcard.2006.03.05716923466Search in Google Scholar

74. T. Hasunuma, M. Nakamura, T. Yachi, N. Arisawa, K. Fukushima, H. Iijima and Saito Y. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine, J. Clin. Ther. Med. 19 (2003) 381-389.Search in Google Scholar

75. Y. Shitara, T. Itoh, H. Sato, A. P. Li and Y. Sugiyam, Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A, J. Pharmacol. Exp. Ther. 304 (2003) 610-616.10.1124/jpet.102.04192112538813Search in Google Scholar

76. S. G. Simonson, A. Raza, P. D. Martin, P. D. Mitchell, J. A. Jarcho, C. D. Brown, A. S. Windass and D. W. Schneck, Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine, Clin. Pharmacol. Ther. 76 (2004) 167-177.10.1016/j.clpt.2004.03.01015289793Search in Google Scholar

77. J. Tong, G. Laport and R. Lowsky, Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma, Bone Marrow Transplant. 36 (2005) 739-740.10.1038/sj.bmt.170512816086041Search in Google Scholar

78. A. Lasocki, B. Vote, R. Fassett and E. Zamir, Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis, Ocul. Immunol. Inflamm. 15 (2007) 345-346.10.1080/0927394070137514717763133Search in Google Scholar

79. S. Vives, M. Batlle, E. Montané and J. M. Ribera, Rhabdomyolysis and renal failure secondary to interaction between simvastatin, ciclosporin A and risperidone in an allogeneic stem cell transplantation patient, Med. Clin. (Barc). 131 (2008) 676.Search in Google Scholar

80. J. W. Park, R. Siekmeier, M. Merz, B. Krell, S. Harder, W. März, D. Seidel, S. Schüler and W. Gross, Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A, Int. J. Clin. Pharmacol. Therapeut. 40 (2002) 439-450.10.5414/CPP4043912395976Search in Google Scholar

81. M. Veeraputhiran and M. Sundermeyer, Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin, Clin. Lung Cancer 9 (2008) 232-234; DOI: 10.3816/CLC. 2008.n.036.Search in Google Scholar

82. P. F. Katsakiori, E. P. Papapetrou, D. S. Goumenos, G. C. Nikiforidis and C. S. Flordellis, Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients, Indian J. Pharmacol. 43 (2011) 385-388; DOI: 10.4103/0253-7613.83106.10.4103/0253-7613.83106315369821844990Search in Google Scholar

83. R. H. Jacobson, P. Wang and C. J. Glueck, Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone, JAMA. 277 (1997) 296-297.10.1001/jama.277.4.2969002485Search in Google Scholar

84. N. S. Karnik and J. R. Maldonado, Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminiti, Psychosomatics46 (2005) 565-568.Search in Google Scholar

85. Serzone (nefazodone hydrochloride) US prescribing information, Bristol-Myers Squibb Company, January 2005.Search in Google Scholar

86. C. B. Hare, M. P. Vu, C. Grunfeld and H. W. Lampiris, Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death, Clin. Infect. Dis. 35 (2002) 111-112.10.1086/34417912410494Search in Google Scholar

87. P. E. Sax, Strategies for management and treatment of dyslipidemia in HIV/AIDS, AIDS Care 18 (2006) 149-157.10.1080/0954012050016184316338773Search in Google Scholar

88. P. H. Hsyu, M. D. Schultz-Smith, J. H. Lillibridge, R. H. Lewis and B. M. Kerr, Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin, Antimicrob. Agents Chemother. 4 (2001) 3445-3450.10.1128/AAC.45.12.3445-3450.20019085111709322Search in Google Scholar

89. R. A. Carr, A. K. Andre, R. J. Bertz, W. Lam, M. Chang, P. Chen, P. Williams, B. Bernstein and E. Sun, Concomitant administration of ABT-378/ritonavir. Results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin, 40th ICAAC, Toronto, September 2000, presentation 1644.Search in Google Scholar

90. C. J. Fichtenbaum, J. G. Gerber, S. L. Rosenkranz, Y. Segal, J. A. Aberg, T. Blaschke, B. Alston, F. Fang, B. Kosel, F. Aweeka and NIAID AIDS Clinical Trials Group, Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047, AIDS 16 (2002) 569-577.10.1097/00002030-200203080-0000811873000Search in Google Scholar

91. J. A. Aberg, S. L. Rosenkranz, C. J. Fichtenbaum, B. L. Alston, S. W. Brobst, Y. Segal, J. G. Gerber and ACTG A5108 team, Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108, AIDS 20 (2006) 725-729.10.1097/01.aids.0000216373.53819.92145928916514303Search in Google Scholar

92. P. A. Pham, C. J. la Porte L. S., Lee, R. van Heeswijk, J. P. Sabo, M. M. Elgadi, P. J. Piliero, P. Barditch-Crovo, E. Fuchs, C. Flexner and D. W. Cameron, Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers, Antimicrob. Agents Chemother. 53 (2009) 4385-4392; DOI: 10.1128/AAC.00449-09.10.1128/AAC.00449-09276416819667285Search in Google Scholar

93. R. Stern, R. Abel, G. L. Gibson and J. Besserer, Atorvastatin does not alter the anticoagulant activity of warfarin, J. Clin. Pharmacol. 37 (1997) 1062-1064.10.1002/j.1552-4604.1997.tb04288.x9506000Search in Google Scholar

94. H. Hickmott, H. Wynne and F. Kamali, The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements, Thromb. Haemost. 89 (2003) 949-950.10.1055/s-0037-1613486Search in Google Scholar

95. J. C. Lin, M. K. Ito, S. N. Stolley, A. P. Morreale and D. B. Marcus, The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin, J. Clin. Pharmacol. 39 (1999) 86-90.10.1177/009127099220075989987704Search in Google Scholar

96. E. A. Sconce, T. I. Khan, A. K. Daly, H. A. Wynne and F. Kamali, The impact of simvastatin on warfarin disposition and dose requirements, J. Thromb. Haemost. 4 (2006) 1422-1424.10.1111/j.1538-7836.2006.01974.x16706996Search in Google Scholar

97. T. Westergren, P. Johansson and E. Molden, Probable warfarin-simvastatin interaction, Ann. Pharmacother. 41 (2007) 1292-1295.10.1345/aph.1K16717565042Search in Google Scholar

98. S. Ahmad, Lovastatin warfarin interaction, Arch. Intern. Med. 150 (1990) 2407.10.1001/archinte.1990.00390220135030Search in Google Scholar

99. H. S. Hoffman, The interaction of lovastatin and warfarin, Conn. Med. 56 (1992) 107.Search in Google Scholar

100. E. A. Iliadis and M. F. Konwinski, Lovastatin during warfarin therapy resulting in bleeding, PAMed. 98 (1995) 31.Search in Google Scholar

101. S. S. Kline and C. C. Harrell, Potential warfarin-fluvastatin interaction, Ann. Pharmacother. 31 (1997) 790.Search in Google Scholar

102. L. E. Trilli, C. L. Kelley, S. L. Aspinall and B. A. Kroner, Potential interaction between warfarin and fluvastatin, Ann. Pharmacother. 30 (1996) 1399-1402.10.1177/1060028096030012078968451Search in Google Scholar

103. M. J. Murphy and M. H. Dominiczak, Efficacy of statin therapy: possible effect of phenytoin, Postgrad. Med. J. 75 (1999) 359-360.10.1136/pgmj.75.884.359174126310435174Search in Google Scholar

104. K. M. Tan, J. G. Kelly and K. McGarry, Statins and phenytoin interact - a case history, Br. J. Clin. Pharmacol. 65 (2008) 147-148.10.1111/j.1365-2125.2007.02982.x229127917610524Search in Google Scholar

105. C. Kyrklund, J. T. Backman, K. T. Kivistö, M. Neuvonen, J. Laitila and P. J. Neuvonen, Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations, Clin. Pharmacol. Ther. 68 (2000) 592-597.10.1067/mcp.2000.11141411180018Search in Google Scholar

106. C. Kyrklund, J. T. Backman, M. Neuvonen and P. J. Neuvonen, Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects, Br. J. Clin. Pharmacol. 57 (2004) 181-187.10.1046/j.1365-2125.2003.01972.x188443214748817Search in Google Scholar

107. R. Eggertsen, A. Andreasson and L. Andrén, Effects of treatment with a commercially available St John’s Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin, Scand. J. Prim. Health Care 25 (2007).10.1080/02813430701442768337977417846933Search in Google Scholar

108. K. Sugimoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi, K. Harada, M. Arakawa, K.\ Sakamoto, M. Masada, I. Miyamori and A. Fujimura, Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin, Clin. Pharmacol. Ther. 70 (2001) 518-524.10.1067/mcp.2001.12002511753267Search in Google Scholar

109. W. C. Lau, L. A. Waskell, P. B. Watkins, C. J. Neer, K. Horowitz, A. S. Hopp, A. R. Tait, D. G. Carville, K. E. Guyer and E. R. Bates, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction, Circulation 107 (2003) 32-37.Search in Google Scholar

110. A. Blagojevic, J. A. Delaney, L. E. Lévesque, N. Dendukuri, J. F. Boivin and J. M. Brophy, Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study, Pharmacoepidemiol. Drug Saf. 18 (2009) 362-369; DOI: 10.1002/pds.1716.10.1002/pds.171619253920Search in Google Scholar

111. O. Gorchakova, N. von Beckerath, M. Gawaz, A. Mocz, A. Joost, A. Schömig and A. Kastrati, Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting, Eur. Heart J. 25 (2004) 1898-1902.10.1016/j.ehj.2003.10.03915522468Search in Google Scholar

112. J. V. Mitsios, A. I. Papathanasiou, F. I. Rodis, M. Elisaf, J. A. Goudevenos and A. D. Tselepis, Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes, Circulation 109 (2004) 1335-1338.10.1161/01.CIR.0000124581.18191.1515023882Search in Google Scholar

113. I. Muller, F. Besta, C. Schulz, Z. Li, S. Massberg and M. Gawaz, Effects of statins on platelet inhibition by a high loading dose of clopidogrel, Circulation 108 (2003) 2195-2197.10.1161/01.CIR.0000099507.32936.C014568892Search in Google Scholar

114. J. Saw, D. M. Brennan, S. R. Steinhubl, D. L. Bhatt, K. H. Mak, K. Fox and E. J. Topol, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial, J. Am. Coll. Cardiol. 50 (2007) 291-295.10.1016/j.jacc.2007.01.09717659194Search in Google Scholar

115. V. L. Serebruany, M. G. Midei, A. I. Malinin, B. R. Oshrine, D. R. Lowry, D. C. Sane, J. F. Tanguay, S. R. Steinhubl, P. B. Berger, C. M. O’Connor and C. H. Hennekens, Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study, Arch. Intern. Med. 164 (2004) 2051-2057.Search in Google Scholar

116. P. Vinholt, T. S. Poulsen, L. Korsholm, S. R. Kristensen, J. Hallas, P. Damkier and H. Mickley, The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease, Thromb. Haemost. 94 (2005) 438-443.Search in Google Scholar

117. A. Zahno, K. Brecht, M. Bodmer, D. Bur, D. A. Tsakiris and S. Krähenbühl, Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro, Br. J. Pharmacol.161 (2010) 393-404; DOI: 10.1111/j.1476-5381.2010.00881.x.10.1111/j.1476-5381.2010.00881.xSearch in Google Scholar

118. L. R. Whitfield, A. R. Porcari, C. Alvey, R. Abel, W. Bullen and D. Hartman, Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin, J. Clin. Pharmacol. 51 (2011) 378-388; DOI: 10.1177/0091270010366446.10.1177/0091270010366446Search in Google Scholar

119. J. S. Wang, M. Neuvonen, X. Wen, J. T. Backman and P. J. Neuvonen, Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes, Drug Metab. Dispos. 30 (2002) 1352-1356.10.1124/dmd.30.12.1352Search in Google Scholar

120. X. Wen, J. S. Wang, J. T. Backman, K. T. Kivistö and P. J. Neuvonen, Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9, Drug Metab. Dispos. 29 (2001) 1359-1361.Search in Google Scholar

121. H. Fujino, I. Yamada, S. Shimada, M. Hirano, Y. Tsunenari and J. Kojima, Interaction between fibrates and statins - metabolic interactions with gemfibrozil, Drug Metabol. Drug Interact. 19 (2003) 161-176.10.1515/DMDI.2003.19.3.161Search in Google Scholar

122. J. T. Backman, C. Kyrklund, K. T. Kivistö, J. S. Wang and P. J. Neuvonen, Plasma concentrations of active simvastatin acid are increased by gemfibrozil, Clin. Pharmacol. Ther. 68 (2000) 122-129.10.1067/mcp.2000.108507Search in Google Scholar

123. T. C. Goosen, J. N. Bauman, J. A. Davis, C. Yu, S. I. Hurst, J. A. Williams and C. M. Loi, Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid, Drug Metab. Dispos. 35 (2007) 1315-1324.10.1124/dmd.107.015230Search in Google Scholar

124. C. Kyrklund, J. T. Backman, K. T. Kivistö, M. Neuvonen, J. Laitila and P. J. Neuvonen, Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate, Clin. Pharmacol. Ther. 69 (2001) 340-345.10.1067/mcp.2001.115542Search in Google Scholar

125. C. Kyrklund, J. T. Backman, M. Neuvonen and P. J. Neuvonen, Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance, Clin. Pharmacol. Ther. 73 (2003) 538-544.10.1016/S0009-9236(03)00052-3Search in Google Scholar

126. P. Mathew, T. Cuddy, W. G. Tracewell and D. Salazar, An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers, Clin. Pharmacol. Ther. 75 (2004) 33.Search in Google Scholar

127. J. D. Spence, C. E. Munoz, L. Hendricks, L. Latchinian and H. E. Khouri, Pharmacokinetics of the combination of fluvastatin and gemfibrozil, Am. J. Cardiol. 76 (1995) 80A-83A.Search in Google Scholar

128. N. Bizzaro, E. Bagolin, L. Milani, C. Cereser and B. Finco, Massive rhabdomyolysis and simvastatin, Clin. Chem. 38 (1992) 1504.Search in Google Scholar

129. R. A. Boyd, R. H. Stern, B. H. Stewart, X. Wu, E. L. Reyner, E. A. Zegarac, E. J. Randinitis and L. Whitfield, Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion, J. Clin. Pharmacol. 40 (2000) 91-98.10.1177/0091270002200861210631627Search in Google Scholar

130. C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. März, J. P. Reckless and E. A. Stein, Risk for myopathy with statin therapy in high-risk patients, Arch. Intern. Med. 163 (2003) 553-564.10.1001/archinte.163.5.55312622602Search in Google Scholar

131. P. D. Thompson, P. Clarkson and R. H. Karas, Statin-associated myopathy, JAMA 289 (2003) 1681-1690. 10.1001/jama.289.13.168112672737Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo